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Introduction: The introduction of an HPV immunisation programme in England should result in a sig-
niﬁcant reduction in the prevalence of vaccine type infections in young women. Here we describe
type-speciﬁc HPV prevalence in three samples of the young female population in England, prior to the
beginning of mass immunisation in 2008.
Methods: Residual vulva-vaginal swab samples from females aged under 25 years undergoing chlamydia
testing as part of the National Chlamydia Screening Programme (NCSP) or Prevention of Pelvic Infection
(POPI) trial were collected from sites across England, together with available demographic and sexual
behaviour data. Residual samples were screened for HPV infection using the Hybrid Capture 2 (hc2) HPV
DNA Test, including the high-risk (HR) and low-risk (LR) probes. Hc2 positive samples were genotyped
using the Roche Linear Array (LA) HPV Genotyping Test.
Results: A total of 3829 samples were included: 2369 from 16 to 24 year old NCSP participants, 275 from
13 to 15 year old NCSP participants and 1185 from 16 to 24 year old POPI participants. Variations in
HPV prevalence between and within the different samples followed a pattern largely consistent with
differences in sexual behaviour. The prevalence of total HR HPV infection, of HPV 16 and/or 18 (16/18)
infection and of ﬁve HR HPV types closely related to HPV 16/18 (HPV 31, 33, 45, 52 or 58) amongst 16–24
year old NCSP participants was 35% (95% CI 33–37%), 18% (95% CI 16–19%), and 16% (95% CI 14–18%),
respectively. Risk of HR HPV infection increased with age during the teen years and was higher in women
who reported two or more sexual partners in the last year and in women with chlamydia infection.
Approximately half of women with HPV 16/18 infection also had another non-vaccine HR HPV type
present.
Conclusions: Prior to HPV immunisation, there was a high prevalence of HPV infections in the lower
genital tract of young, sexually
prevalence closely reﬂected ag
impact of HPV immunisation o
can be measured, in order to in
Abbreviations: CI, conﬁdence interval; CO, cutoff; GP, general practice; hc2, Hybrid Cap
R, high risk; IQR, inter-quartile range; LA, Linear Array HPV Genotyping test; LBC, liquid b
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. Introduction
The recent introduction of human papillomavirus (HPV) vac-
ines offers a new opportunity in the prevention of cervical cancer.
PV vaccines are highly efﬁcacious in preventing both HPV 16 and
8 infections and associated precancerous lesions in clinical tri-
ls; however the vaccines do not appear to alter the outcomes of
xisting infections [1–3]. In England, a routine HPV immunisation
rogramme for 12–13 year old girls, with catch-up immunisation
or girls up to 18 years, started in September 2008. By routinely
argeting pre-teenage girls, in a school-based setting, the immuni-
ation programme aims to gain the highest coverage possible prior
o exposure to infection.
Several  studies have shown that many women attending for
ervical screening have acquired HPV infection by the age of 25
ears [4,5]. There are, however, very few data on the frequency of
PV infections in younger women in England. A single seropreva-
ence survey that described the pattern of age-speciﬁc acquisition
f infection in a general population sample [6] and rates of geni-
al warts diagnoses in genitourinary clinics [7] have both shown a
teep rise in infection during late teenage years.
It is predicted, based on modelling, that in the United Kingdom
UK) HPV vaccination of 12 year old girls is likely to prevent 40–80%
f cervical cancers after 60 years and be cost-effective [8,9]. The
nitial impact of the programme should be to reduce HPV 16 and
8 infection prevalence in young women and the extent of this fall
hould help to better predict the later impact on pre-cancerous dis-
ase and cervical cancer. Measuring the impact of vaccination on
PV infection prevalence in young sexually active women  is a fea-
ible near-term endpoint for HPV immunisation monitoring [10].
dditionally, evaluating the impact of HPV 16/18 immunisation on
ther high-risk HPV types, particularly any cross-protection against
losely related types, will be important to inform potential changes
o vaccine policy and cervical screening strategies.
Here, we report on genital HPV type-speciﬁc DNA prevalence, by
ge, in three samples of the under 25 years, sexually active, female
opulation, in England, prior to mass HPV immunisation. These
ata provide baseline HPV prevalence estimates from unvaccinated
omen in the pre-immunisation period, against which changes in
he post-immunisation period can be measured.
. Methods
.1. Sample and data collection
Residual  vulva-vaginal swab (VVS) samples from women  under-
oing chlamydia testing were collected from ﬁve National Health
ervice (NHS) pathology laboratories conducting testing for the
ational Chlamydia Screening Programme (NCSP) and from an
rchive of samples collected as part of the Prevention of Pelvic
nfection (POPI) randomised controlled trial of chlamydia screening
11].
Laboratories were invited to participate based on the number of
CSP VVS samples processed and the population served, in order
o meet our target study size with a geographically widespread
ample. Participating laboratories submitted anonymous residual
amples to the Health Protection Agency (HPA) from January 2008
o September 2008. Routine (unfrozen) screening samples (i.e. not
hose identiﬁable as diagnostic, symptomatic or partner notiﬁca-
ion tests) from women aged under 25 years, collected from three
CSP recruitment venue types (general practice, youth clinics andamily planning clinics) were eligible for inclusion. For each sample,
ge, year of birth, ethnicity, gender, recruitment venue, reason for
est, date of sample collection, chlamydia test result, and whether
hey reported a new sexual partner in the previous three monthse 30 (2012) 3867– 3875
(termed  new sexual partner for brevity) and two  or more sexual
partners in the previous 12 months (termed multiple sexual part-
ners for brevity) were obtained from the NCSP dataset. All links to
potentially identifying data were broken after extraction of these
variables from the NCSP database and prior to HPV testing.
The  POPI trial had recruited young women (under 28 years)
attending universities and further education colleges in London
between 2004 and 2006 to a study of the impact of chlamydia
screening on pelvic inﬂammatory disease [11]. Women  who had
never had sexual intercourse, had been tested for chlamydia in the
previous three months or were pregnant were excluded. Archived
(at −80 ◦C) ﬁrst (trial entry) samples from women aged under 25
years were sent to the HPA for HPV testing. For each sample, age,
year of birth, ethnicity, date of sample collection, chlamydia test
result, and number of sexual partners in the previous 12 months
were obtained from the POPI database.
2.2. Sample processing and HPV testing
NCSP samples were received and processed at HPA in a median
(inter-quartile range (IQR)) of 5 (3–7) weeks from collection. POPI
samples were retrieved from archive and defrosted at 4 ◦C. Two
aliquots of 300 L each were centrifuged (13,000 × g, 5 min) and
the cellular pellets stored at −25 ◦C prior to testing (one pellet
was resuspended in 300 L phosphate buffered saline (PBS) before
storage).
The samples were screened for the presence of HPV using the
Hybrid Capture 2 HPV DNA test (hc2; originally developed by the
Digene Corporation, and now marketed by Qiagen). The Combined-
Probe Cocktail Method was used to detect high-risk (HR; HPV 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) and low-risk (LR;
HPV 6, 11, 42, 43 and 44) HPV types. The hc2 test was  conducted
according to the manufacturer’s instructions with some modiﬁca-
tions necessitated by the use of VVS samples. Brieﬂy, the cellular
pellet was resuspended in 75 L Specimen Transport Medium with
Denaturation Reagent. Cells were then denatured under alkaline
conditions and hybridized with a pool of HR and LR RNA probes.
The resulting HPV DNA:RNA hybrids were captured onto microtiter
plates with antibodies speciﬁc for DNA:RNA hybrids and detected
using alkaline phosphatase-conjugated anti-DNA:RNA antibody in
conjunction with a chemiluminescent substrate. If the signal out-
put, in relative light units (RLU), was  above the test cutoff (CO) the
sample was considered to contain HPV DNA (i.e. RLU/CO > 1).
Hc2 positive samples were genotyped using the Linear Array
HPV Genotyping test (LA; Roche Molecular Systems). DNA was
extracted from 300 L of the PBS-resuspended cellular pellet using
the automated BioRobot Universal platform (Qiagen, UK) using the
QIAamp® DNA Blood BioRobot® MDx  kit and the extraction pro-
tocol QIAamp ‘One for All UNIV rcV23’. Extracted DNA (50 L of
100 L total eluate) was then ampliﬁed using the PGMY primer
reagents provided in the LA kit. LA can detect 37 HPV types (HPV
6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58,
59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73 (MM9), 81, 82 (MM4),
83 (MM7), 84 (MM8), IS39, and CP6108) and includes a beta-globin
probe to check for sample integrity. The presence of HPV 52 was
deﬁned by reactivity to the oligonucleotide probe 52 M (which
hybridises with HPV genotypes 33, 35, 52 and 58) when there was
no cross-reactivity to the individual oligonucleotide probes for HPV
33, 35 and 58. HPV 52 would not have been identiﬁed if present in
co-infection with HPV 33, 35 or 58. As genotyping was only con-
ducted on those samples found to be positive by hc2, HPV types
26, 40, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73 (MM9),
81, 82 (MM4), 83 (MM7), 84 (MM8), IS39, and CP6108 would only
have been identiﬁed in co-infection with one or more of the types
included on the hc2 probes or through cross-reactivity to probes
not directly targeting the type [12].
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The volume of VVS samples submitted to the study varied and a
orkable sample volume was determined to be 300 L of start-
ng material for both hc2 and LA. VVS samples were estimated
o contain only 7% of the cellular material found in liquid based
ytology (LBC) samples (median 345,362 [IQR: 166,540–538,063]
n = 29) and 4,932,320 [IQR: 2,211,951–8,687,917] (n = 51) cell
quivalents respectively), using a TaqMan®-based real-time PCR
or glyceraldehyde-3-phosphate dehydrogenase [13].
A  small panel of LBC samples (n = 64; 43 positive by LA, 21 neg-
tive) were evaluated in hc2 at (i) the recommended input volume
or LBC samples; and (ii) with the input volume normalized to the
ell equivalents found in 300 L of VVS samples. At the recom-
ended input volume the sensitivity of hc2 compared to LA was
8% and at the level of cell equivalents used in this study it was 77%.
oth of these cellular concentrations had a speciﬁcity of 100%. The
esults for LBC samples at the recommended input were consistent
ith the literature [14–16].
For  LA, the VVS sample input was estimated to contain
pproximately 70% of the cell equivalents of the manufacturer rec-
mmended volume of LBC sample (ca. 17,270 compared to ca.
4,660 cell equivalents respectively [4]). This difference was not
xpected to have an impact on the performance of LA.
.3.  Data analysis
HR  HPV types were deﬁned according to the 2009 International
gency Research on Cancer classiﬁcation of types which were at
east ‘probably carcinogenic to humans’ in the cervix: HPV 16, 18,
1, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 [17]. These types are all
ncluded on the hc2 high risk probe and identiﬁed by LA.
One  DNA extraction run of 88 hc2 positive samples (being pro-
essed for subsequent genotyping) failed. We  excluded from the
nalysis all samples included on the four hc2 plates from which
hese 88 samples originated (thereby excluding a further 187 eligi-
le samples). An additional 15 hc2 positive samples had invalid LA
esults.
Sampling weights were applied to the data for three purposes:
i) to adjust for invalid (hence missing) LA results, weights were
pplied to the valid genotyping results to correct the prevalence
stimates for these missing LA results; (ii) to adjust for differ-
nces in the number of samples submitted by each laboratory,
ata for NCSP samples were weighted so that each laboratory con-
ributed equally to the analysis, rather than in proportion to the
umber of samples submitted; and (iii) to estimate population-
ased prevalence in 16–24 year old females from our convenience
ample of women testing for chlamydia, further weights were
pplied based on the known age-structure and reported sexual
istory (ever having had sexual intercourse and multiple sexual
artners in the previous year) of 16–24 year olds included in
ritain’s second National Survey of Sexual Attitudes and Lifestyles
18]. All analyses were adjusted by weighting for missing LA
esults and for differences in sample-submission by laboratories.
eights by age-structure and sexual history were applied to deter-
ine population-based prevalence estimates. This was necessary
ecause the age-structure and sexual history of our study group dif-
ered from that of the general population of 16–24 year old females
18]: our sample was all sexually active and was  over-represented
y 16–19 year olds and by women who had multiple sexual part-
ers in the previous year, compared with that of the sexually active
eneral population of 16–24 year old women. Conﬁdence intervals
95%) were calculated around prevalence estimates.
Our study included three samples of the female population,
ach with different selection characteristics and different preva-
ence ﬁndings. These were: (1) 16–24 year old NCSP participants, (2)
3–15 year old NCSP participants, and (3) 16–24 year old POPI par-
icipants. Analyses were conducted and presented separately fore 30 (2012) 3867– 3875 3869
these three groups. Group 1, NCSP participants aged 16–24 years,
was the group of primary interest for baseline data as repeat sur-
veys are planned to re-sample from this group in coming years.
The other two groups add insights into infection frequency at ages
included in the catch-up immunisation programme (group 2) and
infection frequency by ethnic group and in London educational set-
tings (group 3), thus giving a more comprehensive picture of HPV in
young females in England. Logistic regression methods were used
to explore associations between HPV infection and age, submit-
ting laboratory, recruitment venue, ethnicity, sexual behaviour and
chlamydia infection. Data analyses were conducted using Stata v11.
3. Results
3.1. Study population
The  numbers of samples submitted, eligible for inclusion and
tested are shown in Fig. 1. A total of 3829 samples were included in
the analysis: 2369 from NCSP 16 to 24 year olds (group 1), 275 from
13 to 15 year old NCSP participants (group 2) and 1185 from 16 to
24 year old POPI participants (group 3). Characteristics of the three
groups of our study population are compared in Table 1. More than
90% of NCSP participants and 65% of POPI participants were of white
ethnicity: 84% of 15–24 year olds in England are of white ethnicity
[19]. Data on sexual behaviour characteristics were available for
around 80% of samples from NCSP participants and nearly all POPI
participants (99.5%) (Table 1). Overall 50% of women included in
our study reported multiple sexual partners, with women recruited
through NCSP reporting multiple sexual partners more often than
those recruited through POPI (Table 1). The youngest NSCP partici-
pants (group 2) were more likely to have had a new sexual partner
(Table 1), and to have had a new sexual partner without also having
multiple partners (21% of group 2 vs. 10% of group 1), which was
consistent with the likelihood that the sampling of these young
women (i.e. their receipt of chlamydia screening) was associated
with their onset of sexual activity. Chlamydia prevalence was high-
est in group 1 (Table 1). Within this group, those recruited through
youth clinics had the highest chlamydia prevalence, of 10.5%, fol-
lowed by family planning at 8.9%, and general practice at 5.8%.
3.2.  HR HPV and HPV 16/18 prevalence
The prevalence of HR HPV was  34.6% (95% CI 32.6–36.7) in 16–24
year old NCSP participants (group 1), and signiﬁcantly lower in
13–15 year old NCSP participants (group 2; 22.6% 95% CI 17.6–28.6)
and in POPI participants (group 3; 18.2% 95% CI 16.1–20.5). HPV 16
and/or 18 (16/18) prevalence was 17.6% (95% CI 16.0–19.3) in group
1, and 11.5% (95% CI 7.7–16.6) and 7.2% (95% CI 5.8–8.8) in groups
2 and 3, respectively.
3.3.  Age-speciﬁc HPV and HPV 16/18 prevalence
HR HPV prevalence increased by year of age in samples from 13
to 24 year old NCSP participants (groups 1 and 2); from ∼20% in
14 year olds to a peak of 39% in 19 year olds, with a fairly stable,
sustained high prevalence (>30%) up to 24 years of age (Fig. 2). HPV
16/18 prevalence showed a similar pattern by age to all HR HPV
prevalence.
3.4. HR HPV and HPV 16/18 risk factors
No difference was found in the prevalence of HR HPV infec-
tion by ethnic group, before or after adjustment for other available
potential confounders (Table 2). The highest HR HPV prevalence
was found in women  of black (including mixed black) ethnicity
(21%) in the POPI trial and in women of white ethnicity (34%)
3870 R. Howell-Jones et al. / Vaccine 30 (2012) 3867– 3875
 of sam
a
p
g
i
t
g
w
T
T
N
u
1
sFig. 1. Inclusion
nd of black (including mixed black) ethnicity (33%) in NCSP
articipants. The lowest prevalence in women from both study
roups was found in women of Asian (including mixed Asian)
.e. Indian Sub continent ethnicity (Table 2). There was  a statis-
ically signiﬁcant difference in HPV 16/18 prevalence by ethnic
roup in POPI participants, due to the low prevalence (0.0%) in
omen of Asian (including mixed Asian) ethnicity (Supplementary
able 1).
able 1
umber (percentage) of samples submitted by each contributing laboratory and the ch
ndergoing chlamydia testing as part of the National Chlamydia Screening Programme 
6–24  year olds participating in the Prevention of Pelvic Infection (POPI) trial.
Group 1: NCSP 16–
(N  = 2369)
Number of samples by laboratory (sample media)
North West: Aintree (Gen-Probe Aptima) 472 (20.1%) 
South West: Cornwall (Cobas Taqman 48) 478 (20.1%) 
East of England: Norfolk and Norwich (Gen-Probe Aptima) 767 (32.2%) 
West Midlands: Stoke (Remel M4RT) 261 (11.1%) 
London: University College London (Gen-Probe Aptima) 391 (16.6%) 
London: St Georges (POPI) (Gen-Probe Aptima) 
Characteristics  of women  included in the analysisa
Mean age (SD) 19.3 (2.4) years 
Ethnicity  (data completeness) (88%) 
White  91.4% 
Black  (including mixed black) 5.3% 
Asian  (including mixed Asian)b 1.4% 
Other  (including Chinese and other) 1.8% 
Recruitment  venue (data completeness) (100%) 
General  practice 23.0% 
Youth  clinic 29.3% 
Family  planning 47.7% 
Education  (POPI) 
Two  or more sexual partners in the previous year 52.3% (81%) 
New  sexual partner in the previous three months 50.3% (81%) 
Chlamydia  trachomatis 8.7% (99%) 
a Data for NCSP samples were adjusted by weighting so that each laboratory contribu
amples.
b Asian, i.e. Indian Sub continent Asian.ples into study.
Women who  reported multiple sexual partners had a signif-
icantly higher risk of HR HPV and HPV 16/18 infection, before
and after adjustment for available data (Table 2). A strong asso-
ciation with chlamydia infection was  also evident for both NCSP
and POPI study populations, and persisted after adjustment for
known potential confounders (Table 2). Reporting a new sexual
partner (groups 1 and 2 only) was  associated with HR HPV and with
HPV 16/18 infection in unadjusted analysis, but did not remain a
aracteristics of women included in study analysis by group: (1) 16–24 year olds
(NCSP), (2) 13–15 year olds undergoing chlamydia testing as part of NCSP and (3)
24 years Group 2: NCSP 13–15 years
(N  = 275)
Group 3: POPI 16–24 years
(N  = 1185)
47 (17.1%)
92 (33.5%)
63 (22.9%)
50 (18.2%)
23 (8.4%)
1185 (100%)
14.6 (0.6) years 19.7 (2.1) years
(87%) (99%)
88.5% 65.2%
9.1% 24.0%
0.4% 2.5%
1.9% 8.3%
(99%) (100%)
12.2%
56.5%
31.3%
100.0%
52.3% (79%) 44.4% (99%)
63.6% (81%) –
5.4% (99%) 5.0% (100%)
ted equally to the analysis by group, rather than in proportion to their number of
R
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Table 2
Variation in HR HPV prevalence by available demographic and sexual behaviour data for women  included in study by groups: groups (1) and (2) 13–24 year olds undergoing chlamydia testing as part of the National Chlamydia
Screening Programme (NCSP) and group (3) 16–24 year olds participating in the Prevention of Pelvic Infection (POPI) trial.
Groups 1 and 2: NCSP 13–24 years Group 3: POPI 16–24 years
% (95% CI) OR (95% CI) Adjusted ORa
(95% CI)
Nu, Nw % (95% CI) OR (95% CI) Adjusted OR
(95%  CI)b
N
Age-band
Under 16 years 22.6 (17.6–28.6) 0.6 (0.4–0.9) 0.6 (0.4–0.9) 275, 275
16–18  years 34.1 (31.1–37.3) Reference Reference 1054, 1047 16.2 (12.8–20.3) Reference Reference 370
19–21  years 35.8 (32.4–39.5) 1.1 (0.9–1.3) 1.3 (1.0–1.6) 809, 803 20.1 (17.0–23.6) 1.3 (0.9–1.8) 1.4 (1.0–2.0) 571
22–24  years 33.8 (29.6–38.3) 1.0 (0.8–1.3) 1.1 (0.9–1.5) 506, 519 16.8 (12.6–22.0) 1.0 (0.7–1.6) 1.1 (0.7–1.8) 244
p < 0.01 p < 0.01 p = 0.25 p = 0.16
Sample source
Aintree 36.0 (32.0–40.2) Reference Reference 519, 529
Cornwall  34.0 (30.2–38.1) 0.9 (0.7–1.2) 0.9 (0.6–1.2) 570, 529
Norfolk  and Norwich 27.1 (24.1–30.3) 0.7 (0.5–0.8) 0.6 (0.4–0.8) 830, 529
Stoke  38.3 (32.9–43.9) 1.1 (0.8–1.5) 1.1 (0.8–1.5) 311, 529
University  College London 31.5 (27.2–36.3) 0.8 (0.6–1.1) 0.8 (0.6–1.2) 414, 529
POPI  trial 18.2 (16.1–20.5) 1185
p < 0.01 p < 0.01
Recruitment venue
General  practice 32.1 (28.4–36.1) Reference Reference 654, 578
Family  planning 32.0 (29.3–34.8) 1.0 (0.8–1.2) 0.9 (0.7–1.2) 1282, 1215
Youth 36.5 (32.8–40.3) 1.2 (1.0–1.5) 1.0 (0.7–1.3) 704, 846
Education  18.2 (16.1–20.5) 1185
p = 0.11 p = 0.80
Ethnicity
White 34.3 (32.2–36.5) Reference Reference 2163, 2130 17.6 (15.0–20.4) Reference Reference 769
Black  (including mixed black) 33.2 (24.5–43.2) 1.0 (0.6–1.5) 1.2 (0.7–2.1) 105, 134 21.2 (16.8–26.4) 1.3 (0.9–1.8) 1.3 (0.9–1.8) 283
Asian  (including mixed Asian)c 17.2 (6.5–38.2) 0.4 (0.1–1.2) 0.4 (0.1–1.1) 26, 31 10.3 (3.4–27.6) 0.5 (0.2–1.8) 0.5 (0.2–1.8) 29
Other  (including Chinese and other) 25.6 (13.7–42.5) 0.7 (0.3–1.4) 0.8 (0.4–1.8) 36, 43 15.3 (9.4–23.9) 0.8 (0.5–1.5) 0.9 (0.5–1.6) 98
p = 0.26 p = 0.21 p = 0.30 p = 0.30
Sexual behaviour
New  sexual partner
No  30.8 (27.8–34.0) Reference Reference 994, 1035
Yes  36.2 (33.2–39.3) 1.3 (1.0–1.6) 1.0 (0.8–1.3) 1149, 1108
p = 0.01 p = 0.77
Multiple sexual partners
No  27.2 (24.3–30.3) Reference Reference 984, 1025 12.2 (9.9–15.0) Reference Reference 655
Yes  39.6 (36.6–42.7) 1.8 (1.4–2.1) 1.7 (1.3–2.2) 1157, 1124 25.4 (21.8–29.3) 2.4 (1.8–3.3) 2.4 (1.7–3.2) 524
p < 0.01 p < 0.01 p < 0.01 p < 0.01
Chlamydia trachomatis
No  31.7 (29.7–33.8) Reference Reference 2395, 2397 17.3 (15.2–19.6) Reference Reference 1126
Yes  51.3 (44.2–58.3) 2.3 (1.7–3.1) 1.8 (1.3–2.5) 221, 218 35.6 (24.5–48.5) 2.6 (1.5–4.6) 2.3 (1.3–4.1) 59
p < 0.01 p < 0.01 p < 0.01 p < 0.01
Differences between groups tested using Pearson’s 2 (crude analysis) or Wald test (adjusted analysis).
a Adjusted for age-band, region, ethnicity, new sexual partner in previous three months, two  or more sexual partners in the previous year and C. trachomatis infection as appropriate.
b Adjusted for age-band, ethnicity, two  or more sexual partners in the previous year and C. trachomatis infection as appropriate.
c Asian, i.e. Indian Sub continent Asian Abbreviations: HPV, human papillomavirus; OR, odds ratio; Nu, unweighted number of samples; Nw, weighted numbers.
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Bars represent 95% confidence intervals of HR HPV prevalence. 
Abbreviations: HPV: Human papillomavirus, HR: High risk 
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Fig. 2. High risk HPV and Chlamydia trachomatis infection by age for women (a) undergoing chlamydia testing as part of the National Chlamydia Screening Programme (NCSP)
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igniﬁcant risk for HPV infection after adjustment for other factors,
robably due to the risk associated with a new partner being very
ften a component of the risk associated with multiple partners
79% of NSCP participants with a new partner also had multiple
artners) (Table 2).
Within  NCSP participants there was some variation in HPV
revalence by submitting laboratory, with lower prevalence of HR
PV and HPV 16/18 amongst samples collected via Norfolk and Nor-
ich laboratory. There was  no indication that women included in
ur study from Norfolk and Norwich had lower risk behaviour than
omen from other regions, indeed overall they reported higher risk
haracteristics.
There were some indications that the samples from Norfolk and
orwich and from the POPI trial may  have suffered from more
egradation prior to, and/or inhibition at, testing. Hc2 positivity
as lower in samples submitted from Norfolk and Norwich than
hose from other NCSP laboratories (39% vs. 44%, p = 0.02). For sam-
les from both Norfolk and Norwich and the POPI trial, a higher
roportion of hc2 positive samples were LA negative (15% each)and  had an RLU/CO in the low range 1.01–3.99 (41% and 37% respec-
tively) than from the other NCSP laboratories (5%, p < 0.001 and 20%,
p < 0.001 respectively).
3.5. Population estimates of HPV and HPV 16/18 prevalence
Weighting our analysis of 16–24 year olds to the age-structure
and sexual history of the population [18], gave lower prevalence
estimates of HPV. The sexually active population-weighted HR HPV
prevalence was  32.1% (95% CI 29.5–34.9) based on NCSP samples
and 16.0% (95% CI 13.8–18.4) based on POPI data, and for HPV 16/18
was 15.7% (95% CI 13.8–17.9) based on NCSP data and 6.0% (95% CI
4.7–7.6) based on POPI data. Assuming HPV prevalence to be zero
in the proportion of the population who reported not having had
sexual intercourse (17% of 16–24 year olds [18]), our population-
weighted HR HPV prevalence estimate was 26.8% based on NCSP
data and 13.3% based on POPI data, and population-weighted HPV
16/18 prevalence was 13.1% based on NCSP data and 4.9% based on
POPI data.
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Table  3
Prevalence of HPV types and selected groups of HPV types in women included in study by group: (1) 16–24 year olds undergoing chlamydia testing as part of the National
Chlamydia Screening Programme (NCSP), (2) 13–15 year olds undergoing chlamydia testing as part of NCSP and (3) 16–24 year olds participating in the Prevention of Pelvic
Infection (POPI) trial.
HPV infection Group 1: NCSP 16–24 years
(N  = 2369)
Group 2: NCSP 13–15 years
(N  = 275)
Group 3: POPI 16–24 years
(N  = 1185)
[Overall rank of
HR  HPV type]
Prevalence  (95% CI) [HR Rank] Prevalence (95% CI) [HR Rank] Prevalence (95% CI) [HR Rank]
Vaccine types
HPV  16, 18 17.6 (16.0–19.3) 11.5 (7.7–16.6) 7.2 (5.8–8.8)
HPV  16 12.5 (11.1–14.0) [1] 8.1 (5.0–12.8) [1] 5.1 (4.0–6.6) [1] [1]
HPV  18 7.0 (6.0–8.2) [2] 3.7  (1.9–7.2) [6] 2.6  (1.8–3.7) [=3] [3]
HPV  16 and 18 1.9  (1.4–2.6) 0.3 (0.0–2.2) 0.6 (0.3–1.2)
HPV  16, 18 with other HR type(s) 9.8 (8.6,11.2) 7.6 (4.4,12.6) 3.4 (2.5–4.6)
HPV  6, 11 5.8 (4.8–6.9) 4.9 (2.6–8.9) 2.4 (1.6–3.4)
HPV  6 (LR) 4.9 (4.0–5.9) 4.7 (2.4–8.7) 1.9 (1.3–2.9)
HPV  11 (LR) 1.2 (0.7–1.8) 0.2 (0.0–1.5) 0.4 (0.2–1.0)
Types  closely related to vaccine types
A9 species
HPV 16, 31, 33, 35, 52, 58 22.6  (20.9–24.5) 14.0 (10.0–19.1) 10.7 (9.1–12.6)
HPV  31, 33, 35, 52, 58 14.2 (12.7–15.8) 10.3 (6.9–15.3) 6.9 (5.6–8.5)
HPV  52 4.6 (3.7–5.6) [6] 2.8  (1.3–5.8) 2.2 (1.5–3.2) [6] [6]
HPV  31 4.0 (3.2–4.9) 3.0 (1.3–6.5) 2.3 (1.6–3.3) [5]
HPV  58 4.2 (3.4–5.2) 3.2 (1.3–7.4) 1.5 (1.0–2.4)
HPV  33 2.4 (1.8–3.1) 2.0 (0.7–5.2) 0.8 (0.5–1.6)
HPV  35 0.7 (0.4–1.1) 0.7 (0.2–2.9) 0.6 (0.3–1.2)
A7  species
HPV 18, 39, 45, 59, 68 18.5 (16.8–20.2) 11.2 (7.5–16.4) 7.7 (6.3–9.3)
HPV  39, 45, 59, 68 13.5  (12.1–15.1) 8.9 (5.6–14.0) 5.3 (4.2–6.7)
HPV  59 5.6 (4.7–6.7) [4] 6.0 (3.3–10.7) [3] 2.6 (1.8–3.7) [=3] [4]
HPV  39 5.2 (4.3–6.2) [5] 4.2 (1.9–8.9) [5] 1.1 (0.6–1.9) [5]
HPV  45 3.2 (2.5–4.0) 3.0 (1.1–8.0) 1.4 (0.8–2.2)
HPV  68 1.7 (1.2–2.3) 0.0 0.5 (0.2–1.1)
A7  and A9 species combined groups
HPV 31, 33, 45, 52, 58 16.0 (14.4–17.6) 10.5 (6.9–15.7) 7.5 (6.1–9.2)
HPV  31, 33, 45 8.8  (7.6–10.1) 7.1 (4.1–12.0) 4.4 (3.4–5.7)
Other  types
HPV  42 (LR) 6.6 (5.6–7.8) 4.7 (2.6–8.3) 3.2 (2.3–4.4)
HPV  51 6.9 (5.9–8.1) [3] 6.5 (4.0–10.5) [2] 4.2 (3.2–5.5) [2] [2]
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bbreviations: HPV, human papillomavirus; HR, high risk; LR, low risk.
.6. Multiple HPV infections
Multiple  infections were extremely common in this study.
mongst women with any HPV genotype detected, 75.6%, 81.6% and
4.4% of NCSP 16–24 year olds (group 1), NCSP under 16 year olds
group 2) and POPI participants (group 3), respectively, had mul-
iple HPV genotypes. In group 1, only a quarter (24.4%) of women
ith HPV detected had a single type detected: 23.2% had two  types,
9.2% had three types, 14.4% had four types and 18.8% had ﬁve or
ore types. Multiple HPV and HR HPV infections were much less
ommon in POPI participants (group 3) than group 1, consistent
ith the lower risk of infection in the POPI sample. Of women with
 vaccine-type HPV (16/18) infection, over half were also infected
ith a non-vaccine HR type (55.7% (95% CI 50.5–60.8%) in group 1,
5.9% (95% CI 46.7–81.0) in group 2 and 47.1% (95% CI 36.7–57.7)
n group 3).
The  strongest risk factors associated with multiple HR HPV
nfections were similar to those identiﬁed for HR HPV and for
PV 16/18 infections, with multiple HR HPV infection being asso-
iated with multiple sexual partners (21% vs. 12% in those with
nd without multiple sexual partners, adjusted OR 1.9 (1.4–2.6))
nd chlamydia infection (30% vs. 15% prevalence in those with and
ithout chlamydia, adjusted OR 1.8 (1.2–2.7) in NCSP participants
Supplementary Table 2).
.7. Type-speciﬁc prevalenceThe  most common HPV type in each group was HPV 16 (Table 3).
PV 51 and 18 were the next most commonly detected types over-
ll. Although the order varied slightly, there was some consistency10.4) [4] 1.7 (1.1–2.6)
between  the groups in terms of the six most commonly detected
HR types (HPV 16, 18, 39, 51, 52 and 59, with the exceptions of HPV
56 replacing HPV 52 for group 2 and HPV 31 replacing HPV 39 in
group 3, Table 3).
The  prevalence of types closely related to vaccine HPV types and
types against which cross-protection have been reported in clinical
trials are shown in Table 3. HPV types 31, 33, 45, 52 or 58 were
detected in 16% of NCSP 16–24 year olds (group 1), while the subset
of HPV types 31, 33 and 45 against which stronger cross-protection
has been reported were detected in 8.8% (Table 3) [2].
HPV  types 6 and/or 11 were detected in 5.8%, 4.9% and 2.4%
of groups 1, 2 and 3 respectively. In each group, HPV 6 was the
more common infection and overall was present in 85% of HPV
6/11 infections.
4.  Discussion
In our samples of young women  undergoing chlamydia screen-
ing, prior to mass HPV immunisation, HR HPV (particularly types 16,
18 and 51) and multiple HPV infections were common. The preva-
lence of HR HPV, HPV 16/18 and multiple HPV infections showed
similar patterns consistent with epidemiology determined by sex-
ual activity (of women  and of their partners), with strongest and
most consistent associations found for increasing age (up to 19
years), multiple sexual partners and presence of chlamydia infec-
tion. Our baseline, pre-immunisation estimates of vaccine-type
infection (HPV 16/18) prevalence in 16–24 year olds undergoing
routine chlamydia screening through the NCSP sites included in this
study was 18% (95% CI 16–19). Any of the group of ﬁve related HR
HPV types for which vaccine trials have reported cross protection
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HPV 31, 33, 45, 52, 58) were found in 16% (95% CI 14–18) of this
ample of young women.
This  multi-centred, community-based study was  not
opulation-based but instead made use of convenience sources
f residual samples from young women undergoing chlamydia
esting. In 2008/09, 15% of females aged 15–24 years were tested
or chlamydia through the NCSP [20]. Our sample of NSCP par-
icipants was representative of all participants in 2008/09 at our
elected venues. The women included in our survey were sexually
ctive, and had higher risk behaviour than the general population.
SCP participants more commonly report multiple sexual partners
nd non-condom use at last sexual intercourse than the general
opulation [21] and chlamydia positivity amongst NSCP screens
s also higher than estimates of population prevalence [20,22].
e were able to weight our estimates for the known differences
n age-structure and sexual activity, resulting in lower estimates.
or example, our estimate of HPV 16/18 prevalence among the
otal population of 16–24 year olds was around 26% lower, at 13%.
owever, the available variables do not fully describe risk of infec-
ion and therefore our population estimates, even weighted by
hese variables, are still likely to overestimate the true population
revalence.
Sexually active females under 16 years are probably less rep-
esentative of the general population at this age than older NCSP
articipants as they are sexually active relatively young (the
edian age of ﬁrst sexual intercourse for females in the UK is ∼16
ears [23]). We  also had only a small number of samples from this
ge group. The data for these girls are nevertheless of particular
nterest as they provide some information about the prevalence of
PV in girls at the ages being targeted with HPV immunisation and
ho are rarely assessable or included in epidemiological studies of
PV.
The clustering of sample collection from just ﬁve NHS sites
ontributes to uncertainty around estimates extrapolated to the
ider population: the 95% conﬁdence intervals around our HPV
6/18 prevalence amongst NSCP participants aged 16–24 years,
f 16.0–19.3% widens to 13.3–22.8% when allowing for clustered
ollection from ﬁve sites.
VVS  samples were used for this study, which, although not
alidated as a sample type for either hc2 or LA by the test manufac-
urers, have been shown to be suitable for HPV DNA detection and
o have greater sensitivity for HPV than urine [24]. Prevalence esti-
ates from VVS samples are not directly comparable to ﬁndings
rom cervical samples as they are likely to include viruses which
ave not infected the host’s cervical cells, and may  not do so [25].
n cross-sectional prevalence studies such as ours, it is not possi-
le to distinguish transient infections from those that will persist.
he poorer sample quality, either due to degradation of the DNA
fter longer storage (some NCSP samples), freeze–thaw cycles (POPI
amples) or inhibition of tests by sample media, and the reduced
ensitivity of hc2 with our sample type (with lower cellular con-
ent), may  have resulted in HPV prevalence being underestimated
n our study, and more so for single infections (and so overestimat-
ng the proportion of infections with multiple HPV types).
The  lower prevalence of HPV (HR, 16/18 and multiple HR) in
amples from POPI participants compared to women of the same
ge-range participating in the NCSP, probably reﬂects real differ-
nces in the prevalence of infection between these two  populations.
hile some of the differences seen may  be due to other factors,
he lower prevalence is consistent with data from the NCSP where
hlamydia positivity of screens conducted in educational settings is
ess than half that identiﬁed in screens conducted at GP and family
lanning and youth clinics [26].
Previously, Kitchener et al. reported a prevalence of 40% for
R HPV and 15% for HPV 16/18 amongst LBC samples from 20 to
5 year old women attending cervical screening in Manchester ine 30 (2012) 3867– 3875
2001–2003,  using similar testing methods [5]. An earlier study of
young women attending a UK sexual health clinic reported a much
lower prevalence: 12% HPV prevalence in cervical samples from
15 to 19 year old women recruited at a sexual health clinic to a
longitudinal study in Birmingham between 1988 and 1992 [27].
Jit M et al. reported less than 5% of girls under 14 years of age
to have serological evidence of HPV 6, 11, 16 or 18 infection, ris-
ing to over 20% in women aged 18 years and over [6]. As our study
sampled sexually active young women, and was based on HPV DNA
detection, it is not surprising that we found a substantially higher
prevalence of HPV in the youngest teenagers sampled [28]. How-
ever, in common with the seroprevalence data, even amongst our
sexually active sample of young women, there was a steep trend to
increasing HPV prevalence with increasing age, from 13 years up
to at least 16 years.
HPV  vaccines do not impact on infections present at the time
of immunisation [29]. The steep increase in HR HPV prevalence
between the ages of 13 and 16 years supports the decision to deliver
routine HPV immunisation at age 12–13 years. At age 14 years,
assuming 8% of 14 year olds have had sexual intercourse [18] and
an HPV 16/18 prevalence in these girls of up to 9%, then an esti-
mated maximum 0.7% of 14 year old girls had existing infection
with either HPV 16 or 18 at the time of immunisation. The percent-
age of 12 year olds (routine cohort) infected with HPV 16 or 18 at
the time of infection will presumably be lower than that estimated
for 14 year olds. The association between young age at ﬁrst sexual
intercourse and cervical cancer suggests that although these girls
represent an extremely small proportion of the target-population,
they might be at increased future risk of cervical cancer due to early
onset of sexual activity [30] and exposure prior to HPV vaccination.
The proportion of vaccinated girls who  are unlikely to gain full ben-
eﬁt from HPV immunisation will be higher in the catch-up cohorts
(up to 18 years), where for example (by the same logic and assump-
tions) up to 11% of 17 year olds have existing HPV 16/18 infections
(assuming 60% have had sexual intercourse, and HPV 16/18 preva-
lence in these women to be 19%). At a population level, effectiveness
will of course be reduced much more by non-uptake of vaccine.
Girls  vaccinated as part of the routine cohorts (aged 12–13 years)
will turn 16 years and begin to enter the target group for chlamydia
screening (16–24 years) from 2012. We  shall repeat the collection
and testing of samples from 16 to 24 year old NCSP participants
over the coming years to measure the effectiveness of HPV immu-
nisation against vaccine and non-vaccine types, and to estimate the
herd-immunity effects in unvaccinated women.
5. Conclusion
These data provide estimates of the prevalence of vaccine-type
and other HPV type infections in young, sexually active women
in England. They may  be used to inform vaccination policies, as a
baseline against which to measure the impact of the national HPV
16/18 immunisation programme in England on the prevalence of
vaccine-type and non-vaccine-type HPV infections and, through
their inclusion in mathematical models, help predict the impact
of the immunisation programme on HPV-related cervical disease
in future years.
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